Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment

ChangeBridge: Patent Apps - Pharma (A61K)

Published August 9th, 2023

Detected March 27th, 2026

Summary

The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.

View original document View source feed page

What changed

This document is a publication of a United States patent application, specifically US20260083725A1, filed on August 9, 2023. The application, titled 'SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER,' describes a method for treating pancreatic cancer using a Sig-1R ligand. The inventors claim that this ligand inhibits stromal-induced tumor growth and the metastatic process by modulating the dialog between stromal and cancer cell compartments.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property and market exclusivity for treatments targeting pancreatic cancer via Sig-1R ligands. Companies involved in oncology drug development, particularly those researching pancreatic cancer, should be aware of this filing for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER

Application US20260083725A1 Kind: A1 Mar 26, 2026

Inventors

Olivier SORIANI, Mauro-Franck BORGESE, Raphaël RAPETTI MAUSS, Richard TOMASINI, Patricia MELNYK

Abstract

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.